Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

European Innovation Council · Running

TETRAKIT A novel click chemistry-based, universal radiolabelling platform revolutionizing the generation of theranostic radiopharmaceuticals

Coordinator
Tetrakit Technologies Aps, Denmark
Runs
1 July 2025 to 30 June 2027
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101218021

What the project is doing

In the project's own words, from its summary on CORDIS.

TetraKit Technologies (TT) is developing the TetraKit Platform, a universal radiolabelling platform that enables the synthesis of novel therapeutic and diagnostic (theranostic) radiopharmaceuticals (RPs). By overcoming the limitations of currently available radiochemistry solutions, TT will address the unmet need for an innovative approach that makes radiolabeling, specifically with radiohalogens, simple, rapid, effective and scalable.

Based on an ultrafast next generation tetrazine ligation and linker technology, the TetraKit Platform allows labelling of any biomolecule (target vector) with any radiohalogen or radiometal, according to a versatile ‘plug-and-play’ principle. As such, TT will facilitate unleashing the full potential of novel theranostic RPs to serve the need of millions of cancer patients worldwide. To validate the TetraKit Platform, TT seeks EIC Accelerator blended financing to advance the clinical development of the lead asset emerging from the platform, 131I-DualFAPi, an iodine-131-labelled therapeutic RP that targets the fibroblast activation protein (FAP) – THE ‘next billion-dollars theranostics target’.

Initially to be developed for the treatment of metastasized Triple Negative Breast Cancer (TNBC), an aggressive type of cancer with poor survival chances, TT’s lead asset will be the first radiohalogenated FAP-targeting therapeutic RP in clinical development, made possible by the TetraKit Platform. Completion of a Phase 1/2 program in TNBC patients will present a significant value inflection point for TT, which is anticipated to result in a strategic partnership for the final development and commercialization steps.

Successful development of 131I-DualFAPi will be an essential milestone that will allow TT to fully exploit the TetraKit Platform, bringing immense commercial and societal value.

Topics

Who is involved

OrganisationCityCountryRole
Tetrakit Technologies ApsKobenhavnDenmarkCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI